Sugi Predict

Sugi Predict / Compounds / SCHEMBL2544527

SCHEMBL2544527

SCHEMBL2544527

C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ PTGS2 P35354 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ ECE1 P42892 1/20 0.46
▸ MME P08473 2/20 0.44
▸ ACE P12821 2/20 0.44
▸ CPA1 P15085 1/20 0.44
▸ ACE2 Q9BYF1 1/20 0.44
▸ DPP4 P27487 1/20 0.42
▸ PTGS1 P23219 1/20 0.39
▸ GSTK1 Q9Y2Q3 1/20 0.39
▸ OPRD1 P41143 6/20 0.38
▸ OPRM1 P35372 4/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ DPP8 Q6V1X1 1/20 0.38
▸ DPP7 Q9UHL4 1/20 0.38
▸ CTRB1 P17538 3/20 0.37
▸ GLO1 Q04760 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11253834 1.00 ALDH1A1 (0.52) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29589671 0.98 ALDH1A1 (0.50) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29355244 0.98 ALDH1A1 (0.50) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30585206 0.93 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30585204 0.93 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30585205 0.93 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL32680129 0.92 ALDH1A1 (0.44) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30637048 0.90 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29906328 0.87 EGFR (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29454351 0.87 ALDH1A1 (0.47) ALDH1A1LMNAMAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692103-A1 NOVEL TARGETING COMPOUND AND USE THEREOF, AND NUCLEIC ACID CONJUGATE AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2026-02-11 — — EP claimed
EP-4674840-A1 CHEMICAL COUPLING LINKER AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2026-01-07 — — EP claimed
EP-4652183-A1 PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) 2025-11-26 — — EP claimed
WO-2024235130-A9 POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-26 — — WO claimed
WO-2024235136-A9 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO claimed
WO-2024235128-A9 ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO claimed
WO-2024235134-A9 CONJUGATE HAVING TARGETING EFFECT, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO claimed
WO-2024235132-A9 COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO claimed
US-20250170259-A1 COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC POLYNUCLEOTIDES FOR EXON SKIPPING YALE UNIVERSITY 2025-05-29 — — US claimed
US-20250041438-A1 ANTIBODY-DRUG CONJUGATE NOVELTY NOBILITY INC. (KR) 2025-02-06 — — US claimed
WO-2024230763-A1 NOVEL TARGETING COMPOUND AND USE THEREOF, AND NUCLEIC ACID CONJUGATE AND USE THEREOF 广东东阳光药业股份有限公司 2024-11-14 — — WO claimed
CN-118930593-A Novel targeting compounds and nucleic acid conjugates and uses thereof 广东东阳光药业股份有限公司 2024-11-12 — — CN claimed
WO-2024179381-A1 CHEMICAL COUPLING LINKER AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-09-06 — — WO claimed
WO-2024153162-A1 PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) 2024-07-25 — — WO claimed
US-20240140983-A1 SINGLE STRANDED DNA ENZYME INHIBITORS MASSEY UNIVERSITY (NZ) 2024-05-02 — — US claimed
US-20230374112-A1 Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof BDC CAPITAL INC. (CA) 2023-11-23 — — US claimed
WO-2023168427-A1 COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC POLYNUCLEOTIDES FOR EXON SKIPPING YALE UNIVERSITY (US) 2023-09-07 — — WO claimed
WO-2023157989-A1 ANTIBODY-DRUG CONJUGATE 주식회사 노벨티노빌리티 2023-08-24 — — WO claimed
US-11506662-B2 Detection, identification, and purification of degradative and non-degradative enzymes in biological samples THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-11-22 — — US claimed
WO-2022067445-A1 BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF CORPORATION GENACOL CANADA INC. (CA) 2022-04-07 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041438-A1 ANTIBODY-DRUG CONJUGATE KIT, CD99, CD44 ALDH1A1 231/4885LMNA 3085/4885MAPT 2026/4885
US-20240140983-A1 SINGLE STRANDED DNA ENZYME INHIBITORS APOBEC3A, APOBEC3C, APOBEC3G ALDH1A1 1048/4885LMNA 1663/4885MAPT 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.